ArticleExperimental eye research2025
AAV2.7m8 transduction of stage 2 human retinal organoids induces highly variable responses in innate and inflammatory gene expression and cytokine secretion.
Article in Experimental eye research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in neural organoids: structural organization, disease modeling, and applications in gene therapy.Molecular biology reports · 2026Review
- Functional In Vitro Assessment of rAAV-Delivered Retinol Dehydrogenase 12 (RDH12) Activity.International journal of molecular sciences · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The preclinical evaluation of recombinant AAV (rAAV) gene therapy vectors should consider host innate and inflammatory immune responses which can cause harmful ocular inflammation and decrease the efficiency of transgene delivery. In this study we determined which cell types expressed the transgene following transduction of 75-day-old human pluripotent stem cell (hPSC)-derived retinal organoids (RO) with the gene delivery vector AAV2.7m8-CAG-EGFP (AAVGFP). We then examined the changes in RO inflammatory gene expression and cytokine secretion following AAVGFP transduction. Our results indicated that RO cell types including photoreceptors (PR), retinal progenitor cells (RPCs), retinal ganglion cells (RGC), horizontal cells, and amacrine cells were transduced by AAVGFP. PCR array analysis following AAVGFP RO transduction detected up regulation of innate and adaptive immune response genes including chemokine (CC) genes, cluster of differentiation (CD) genes, interleukin (IL) genes, and transcription factors. The changes in gene expression following RO transduction varied drastically depending on the manufacturer and the production lot of AAVGFP, and were also not consistent between RO batches transduced with the same lot of AAVGFP. Analysis of RO supernatants indicated that several pro- and anti-inflammatory cytokines including sCD40L, IL-4, IL-6, IL-10, IL-13, IL-17A and MCP-1 were secreted following AAVGFP transduction, but the secretion pattern of these cytokines varied between transductions. These data indicate that intermediate-stage differentiating human ROs derived from the same hPSC line have highly variable responses to rAAV gene delivery vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.